癌症及其治疗会引起疼痛、疲劳和情绪困扰等症状，影响癌症不同阶段患者的生活质量。虚拟现实 (VR) 已成为解决这些症状的一种有前景的替代方案，它可以让患者沉浸在将患者与现实隔离的虚拟环境中。范围界定审查是按照 PRISMA-ScR（范围界定审查的系统审查和荟萃分析扩展的首选报告项目）指南进行的。检索在 PubMed 和 CINAHL 中进行，直至 2023 年 10 月。确定了与研究主题相关的 23 项主要研究，并收集了以下信息：肿瘤学服务中使用的 VR 类型（沉浸式与非沉浸式）、目的（分散注意力、培训、或放松）、使用的设备（头戴式显示器、耳机或虚拟控制器）以及模拟的环境（自然环境、技能游戏或教育环境）。描述了 VR 对疼痛、疲劳和情绪困扰的影响，强调了其在短期内减轻这些症状的能力。虚拟现实已被证明是减轻癌症患者疼痛、疲劳和情绪困扰的有效技术短期内。护士可以使用 VR 作为补充工具来促进虚拟环境，从而改善对癌症患者的护理，从而提高他们的生活质量。版权所有 © 2024 Wolters Kluwer Health, Inc. 保留所有权利。

Cancer and its treatments cause symptoms such as pain, fatigue, and emotional distress, which affect the quality of life of patients at different stages of cancer. Virtual reality (VR) has emerged as a promising alternative for addressing these symptoms by immersing patients in a virtual environment that isolates them from reality.To describe the existing evidence on the use of VR to improve pain, fatigue, and emotional distress in people with cancer at different stages of the cancer trajectory.A scoping review was conducted following the PRISMA-ScR (Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews) guidelines. Search was conducted in PubMed and CINAHL until October 2023.Twenty-three primary studies related to the study topic were identified, and the following information was collected: type of VR (immersive vs nonimmersive) used in oncology services, purpose (distraction, training, or relaxation), devices used (head-mounted display, headset, or virtual controller), and the environment simulated (natural environment, skill games, or educational environment). The effects of VR on pain, fatigue, and emotional distress are described, highlighting its ability to mitigate these symptoms in the short term.Virtual reality has been shown to be an effective technique for reducing pain, fatigue, and emotional distress in people with cancer in the short term.Nurses can use VR as a complementary tool to promote virtual environments that improve the care for and therefore the quality of life of people with cancer.Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.